EDU 411

EduPharma is a clinical-stage biotechnology company based in South Korea that specializes in the development of small molecule inhibitors for central nervous system (CNS) disorders. The company's research is centered on the Dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A), a protein that plays a critical role in neurodevelopment and is overexpressed in individuals with Down Syndrome. Their lead candidate, EDU-411, is a potent and selective DYRK1A inhibitor currently undergoing Phase 1 clinical trials to evaluate its safety and efficacy in improving cognitive function. Beyond Down Syndrome, EduPharma is exploring the potential of EDU-411 and other pipeline assets for the treatment of Alzheimer's Disease and other neurodegenerative conditions. The company aims to translate cutting-edge kinase research into transformative therapies for patients with significant unmet medical needs.